Articles tagged with Hematology
Matthew Gertzog has been named the American Society of Hematology's next lead staff executive and chief executive officer, succeeding Martha Liggett after 30 years. Gertzog brings nearly 40 years of experience in nonprofit and association management to the role.
A Japan-wide study found that growth hormone therapy improves adult height in childhood stem cell transplant survivors with short stature. However, treatment responses were highly variable and influenced by transplant-related factors such as total body irradiation and chronic graft-versus-host disease.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
A new study found that a simple blood test can accurately identify tuberculosis (TB) among patients, which could help save millions of lives and reduce transmission. The test measures a specific marker called ESAT-6 produced by the TB bacteria.
A new global report highlights opportunities to strengthen diagnosis, treatment, and education for women and girls with hematological conditions. The report calls for earlier diagnosis, more consistent treatment, and stronger research and education to improve outcomes globally.
A novel therapy targeting the bone marrow microenvironment is shown to accelerate recovery and promote hematopoietic regeneration after injury. Pharmacological activation of YAP/TAZ improves BM niche recovery, enhancing engraftment and white blood cell recovery following HSCT.
Researchers have successfully produced genome-edited T cells that can target and destroy cancer cells using the Platinum TALEN genetic engineering technique. The technique was found to be efficient, with an average yield of 72 million 1G4-TCR cells for every 3 million T-cells.
ASH recognizes 11 leaders in hematology, including Elliott Vichinsky and Leon Bernal-Mizrachi, for transformative contributions to patient care and research. The awards highlight their dedication to improving outcomes and addressing health disparities.
A study by Wake Forest University School of Medicine found nearly one in five caregivers reported experiencing food insecurity during their child's hospital stay. Children whose caregivers faced food insecurity stayed in the hospital about a third longer on average, with higher rates of readmission within 30 days.
Dr. Josep Maria Ribera receives the EHA Clinical Excellence Award for his distinguished career in Acute Lymphoblastic Leukaemia treatment and patient care improvements. He is also recognized for his academic mentorship, training numerous haematologists who now lead positions in the field.
A new study by the American Society of Hematology finds that stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults. Gene therapy, while promising, comes with an astronomical cost and requires a significant price reduction to be competitive.
Researchers found that iron deficiency may be more common and diagnosable earlier in U.S. school-aged children using a new method, detecting early stages of iron deficiency by looking at changes in red blood cells.
A study by Osaka Metropolitan University found that women with a higher proportion of LOX cells in their white blood cells had a lower likelihood of achieving natural pregnancy. The researchers suggest combining AMH analysis with LOX measurement may improve prediction of natural conception.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
Sickle cell disease affects an estimated 7.74 million people worldwide, with sub-Saharan Africa accounting for two-thirds of global cases. Individuals living in this region are less likely to use medications or go to the hospital for pain crises, relying more on homeopathic remedies and delaying medical care.
The American Society of Hematology and the International Society on Thrombosis and Haemostasis have released comprehensive guidelines for anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism. The guidelines outline best practices for preventing life-threatening complications in children.
The ASH HematOmics Program platform combines genomics, gene expression, and clinical information from nearly 6,000 patients with blood cancers. Researchers can explore these datasets together in a single open resource, accelerating discovery in hematological malignancies.
A team of researchers at North Carolina State University has created an injectable microgel called B-knob triggered microgels (BK-TriGs) that can help reduce bleeding in infants during surgery. The microgel works by mimicking the mechanical properties of natural platelets, which helps to create fibrin networks and stanch bleeding.
The American Society of Hematology has published clinical practice guidelines for diagnosing and managing severe acquired aplastic anemia, a rare and life-threatening bone marrow failure disorder. The guidelines highlight the importance of shared decision-making between patients and providers, as well as the need for additional researc...
Hematological malignancies are a major global health challenge, with the US and China experiencing distinct epidemiological patterns. The study reveals that NHL is the most common type globally and in the US, while leukemia leads in incidence in China.
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
A study by Yale School of Medicine found that 60% of physicians who treat sickle cell disease reported burnout, compared to 43% of those who do not. The data also showed that less job pride and less recreation time were associated with increased burnout.
A large venous thrombosis trial has found that apixaban is safer than rivaroxaban, with 3.3% of participants experiencing clinically relevant bleeding compared to 7.1% with rivaroxaban. This trial has significant implications for clinical practice and patient care.
A large registry study identifies a specific genetic mismatch linked to severe acute graft-versus-host disease (aGVHD) after cord blood transplantation, tripling the risk of life-threatening complications. Researchers found that a particular HLA combination in donors and recipients increased aGVHD risk by threefold.
A group of nerve cells in the brainstem has been identified as a stabilizing system for blood pressure, preventing fluctuations between daily activities. The study suggests that loss or dysfunction of these cells can lead to unstable blood pressure and is associated with conditions such as multiple system atrophy.
A nationwide study found that periods can trigger severe pain in many women and girls with sickle cell disease, leading to emergency department visits and hospitalizations. The study's authors recommend a routine menstrual history screening as part of annual sickle cell care and connecting patients with reproductive health specialists.
A study found that ultra-endurance running damages red blood cells, reducing their ability to carry oxygen and nutrients. The damage accelerates the aging and breakdown of these cells, with longer races leading to greater damage.
The National Comprehensive Cancer Network has published new guidelines for Pediatric Soft Tissue Sarcomas, highlighting the unique characteristics of this childhood cancer. The guidelines focus on rhabdomyosarcoma (RMS), a subtype with varying genetic changes that influence treatment outcomes.
The American Society of Hematology released guidelines for frontline and relapsed/refractory management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), outlining optimal approaches to treating high-risk patient populations. The guidelines highlight the need for additional research on immunotherapies and tr...
Researchers have developed an open-source pressure myography tool, HemoLens, which reduces the cost of vascular research to $750 from $40,000. The tool uses affordable manufacturing processes and customizable components, making it easier for researchers to study vascular function.
The American Society of Hematology released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening disease of the bone marrow. The guidelines outline best practices for diagnosing the disorder, which typically takes about three years to diagnose.
A study published in EBioMedicine found changes in blood samples from almost 1,000 people hospitalized for COVID-19 may pinpoint patients at risk of long-term lung disease. The study identified elevated levels of certain molecules, which could lead to the development of simple blood tests to detect ongoing lung problems.
Researchers identify circulating extracellular vesicles produced in diseased kidneys as the culprit behind toxicity in the heart. The discovery could lead to the development of a blood test to identify patients at high risk for serious heart problems and novel treatments to prevent and treat heart failure.
A single dose of IV iron dextran is the most cost-effective treatment option for women with heavy menstrual bleeding and iron deficiency anemia. The study found that IV iron dextran improves quality of life and reduces costs compared to oral ferrous sulfate.
Researchers at Kanazawa University have developed a new combination therapy that combines CAR-T cell therapy with a SUMOylation inhibitor, which effectively suppresses MYC activity and slows the growth of Burkitt's lymphoma cells. The approach extends survival rates in mouse models by up to 80%.
Chromatin accessibility maps reveal that MDS stem cells gradually lose their normal identity and acquire characteristics typical of myeloid progenitors. A 'progenitor score' developed by the team tracks cell movement toward a progenitor-like state, correlating with disease severity and prognosis.
Researchers present phase 1 study results of rapcabtagene autoleucel, a rapid CAR-T cell manufacturing platform that reduced production time to under two days. The treatment showed a manageable safety profile and promising antitumor activity, with complete remission rates ranging from 70% to 100% in patients.
NEJM Clinician curates highly relevant clinical insights from over 150 peer-reviewed journals to give physicians clear guidance without the noise. The weekly publication delivers summaries and commentary in a concise, 30-minute read, helping healthcare providers stay informed and confident in their decisions.
Researchers at the University of Cincinnati present a new BTK degrader called Bexobrutideg, showing an 83% overall response rate in relapsed CLL patients. The treatment also shows efficacy in patients with CNS involvement and those with BTK mutations that none of currently approved BTK inhibitors are effective against.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
Researchers from Mass General Brigham Cancer Institute present promising new treatment options for acute myeloid leukemia, autoimmune bleeding disorders, and multiple myeloma. The studies show improved event-free survival, higher overall response rates, and better quality of life for patients treated with novel therapies.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
Serum markers such as NLR, PLR, ESR, LDH, ALP, creatine kinase-BB, SUA, CRP, and CA 15-3/27.29 have been linked to breast cancer diagnosis, prognosis, and therapeutic monitoring. These biomarkers offer affordable, non-invasive, and accessible diagnostic strategies for bridging the diagnostic gap in low-resource settings.
A new study found that engasertib reduced nosebleed frequency and duration in patients with hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder. The trial also showed improved symptoms and safety profile for the drug, paving the way for its potential use as a treatment option.
A recent study found that young donors (18-35 years old) with minor HLA differences can provide better survival rates and outcomes compared to older sibling donors. Additionally, gender and CMV status also play a role in donor selection.
Researchers have developed a system called CytoDiffusion that uses generative AI to study the shape and structure of blood cells. The system can accurately identify normal blood cell appearances and spot unusual or rare cells that may indicate disease, outperforming existing systems in tests.
A University of Delaware study uses robotic testing to gauge perception-based movement in stroke survivors, revealing hidden sensory losses. The researchers hope their findings will encourage clinicians to integrate precision testing into assessments, leading to a personalized medicine approach to treatment.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
A new study by Carnegie Mellon University's Wood Neuro Research Group uses advanced brain imaging and a digital visualization tool to better understand how pain is processed in the brain for people with sickle cell disease. The team found that patients had reduced connectivity across key brain networks linked to pain perception, partic...
A biomarker study found that low placental growth factor (PlGF) levels can predict early-onset preeclampsia in pregnant women with sickle cell disease. The researchers identified a PlGF threshold of 87 pg/mL at 20-24 weeks as effective for predicting early-onset preeclampsia and late-onset preeclampsia, respectively.
Epithelioid hemangioendothelioma is a rare and potentially malignant vascular tumor that can be mistaken for benign conditions. A new case report highlights the diagnostic challenges raised by rare tumors and emphasizes the need for vigilant evaluation of slow-growing swellings.
Mikkael Sekeres has been elected to the Executive Committee of the American Society of Hematology (ASH), a four-year term starting after the 2025 ASH Annual Meeting. He will help strengthen the organization's mission in shaping the future of hematology.
The ASAP study found that transplantation as soon as possible does not provide a survival advantage over remission induction, but reduces hospital stays and chemotherapy exposure. Age and AML genetics are the most important risk factors influencing survival.
A new dual-imaging system simultaneously maps retinal structure and capillary oxygen levels in live mice, allowing researchers to study vision-threatening diseases like glaucoma and diabetic retinopathy. This non-invasive approach offers a powerful tool for elucidating local capillary values and tracking changes in retinal oxygenation.
Researchers at Northern Arizona University are developing a breakthrough tool to detect early signs of Alzheimer's disease. The new technology uses microvesicles in the blood to identify biomarkers indicating improved neuroplasticity, which can help track the disease's progression.
A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
Treatment with exagamglogene autotemcel (exa-cel) leads to clinically meaningful improvements in overall quality of life for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Patients experience substantial improvements in physical, social, functional, and emotional well-being, with sustained benefits...
The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.
St. Jude receives its third consecutive Magnet designation and first Magnet Designation with Distinction, recognizing its commitment to exceptional nursing care and patient outcomes. The hospital's nursing programs, including the Nurse Residency Program and Center of Advanced Practice, have contributed to its success.